Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96131 | 0.78 | CES2 (0.37) | TAAR1GPR17 | |
| SCHEMBL523766 | 0.76 | ACHE (0.43) | TAAR1 | |
| SCHEMBL4048403 | 0.76 | TAAR1 (0.58) | TAAR1 | |
| SCHEMBL3062133 | 0.75 | SLC6A4 (0.31) | — | |
| SCHEMBL24395252 | 0.74 | TAAR1 (0.39) | TAAR1 | |
| SCHEMBL3090749 | 0.74 | SELL (0.38) | TAAR1 | |
| SCHEMBL3082888 | 0.74 | TSHR (0.35) | TAAR1 | |
| SCHEMBL378361 | 0.74 | TAAR1 (0.34) | TAAR1GPR17 | |
| SCHEMBL7592654 | 0.72 | TTR (0.48) | GPR17TTR | |
| SCHEMBL20670791 | 0.70 | CA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | TAAR1 3801/4885GPR17 258/4885TTR 3592/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | TAAR1 3801/4885GPR17 258/4885TTR 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.